"Nov. 20, 2012 -- Oral contraceptives should be made available without a prescription to reduce unintended pregnancies, according to a newly published opinion by the American College of Obstetricians and Gynecologists (ACOG).
Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).
In vitro and animal studies have shown that norethindrone combines high progestational activity with low intrinsic androgenicity. In humans, norethindrone acetate in combination with ethinyl estradiol does not counteract estrogen-induced increases in sex hormone binding globulin (SHBG). Following multiple-dose administration of ESTROSTEP Fe (norethindrone acetate and ethinyl estradiol tablets) , serum SHBG concentrations increase two- to three-fold and free testosterone concentrations decrease by 47% to 64%, indicating minimal androgenic activity.
Acne is a skin condition with a multifactorial etiology, including androgen stimulation of sebum production. While the combination of norethindrone acetate and ethinyl estradiol increases sex hormone binding globulin (SHBG) and decreases free testosterone, the relationship between these changes and a decrease in the severity of facial acne in otherwise healthy women with this skin condition has not been established.
Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, since the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate and ethinyl estradiol are rapidly absorbed, with maximum plasma concentrations of norethindrone and ethinyl estradiol occurring 1 to 2 hours post-dose. Both are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol.
Administration of norethindrone acetate/ethinyl estradiol with a high fat meal decreases rate, but not extent, of ethinyl estradiol absorption. The extent of norethindrone absorption is increased by 27% following administration with food.
Plasma concentrations of norethindrone and ethinyl estradiol following chronic administration of ESTROSTEP Fe (norethindrone acetate and ethinyl estradiol tablets) to 17 women are shown below (Figure 1). Mean steady-state concentrations of norethindrone for the 1/20, 1/30, and 1/35 tablet strengths increased as ethinyl estradiol dose increased over the 21-day dose regimen, due to dose-dependent effects of ethinyl estradiol on serum SHBG concentrations (Table 1). Mean steady-state plasma concentrations of ethinyl estradiol for the 1/20, 1/30, and 1/35 tablet strengths were proportional to ethinyl estradiol dose (Table 1).
FIGURE 1. Mean Steady-State Plasma Ethinyl Estradiol and
Norethindrone Concentrations Following Chronic Administration of ESTROSTEP Fe (norethindrone acetate and ethinyl estradiol tablets)
TABLE 1. Mean (SD) Steady-State Pharmacokinetic ParametersFollowing
Chronic Administration of ESTROSTEP Fe (norethindrone acetate and ethinyl estradiol tablets) a
|Norethindrone Acetate/ Ethinyl Estradiol Dose||Cycle Day||Cmax||AUC||CL/F||SHBGb|
| a Cmax=Maximum plasma concentration;
AUC (0-24)=Area under the plasma concentration-time curve over the dosing
interval; CL/F=Apparent oral clearance
bMean (SD) baseline value=55 (29) nmol/L
No age-related differences were seen in plasma concentrations of ethinyl estradiol and norethindrone following administration of ESTROSTEP Fe (norethindrone acetate and ethinyl estradiol tablets) to 119 postmenarchal women ages 15 to 48 years.
Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg. Plasma protein binding of both steroids is extensive ( > 95%); norethindrone binds to both albumin and sex hormone binding globulin, whereas ethinyl estradiol binds only to albumin. Although ethinyl estradiol does not bind to SHBG, it induces SHBG synthesis. ESTROSTEP Fe (norethindrone acetate and ethinyl estradiol tablets) increases serum SHBG concentrations two- to three-fold (Table 1).
Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites. A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation.
Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites. Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Steady-state elimination half-lives of norethindrone and ethinyl estradiol following administration of ESTROSTEP Fe are approximately 13 hours and 19 hours, respectively.
The effect of race on the disposition of ESTROSTEP Fe (norethindrone acetate and ethinyl estradiol tablets) has not been evaluated.
The effect of renal disease on the disposition of ESTROSTEP Fe (norethindrone acetate and ethinyl estradiol tablets) has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma ethinyl estradiol concentrations were higher and norethindrone concentrations were unchanged compared to concentrations in premenopausal women with normal renal function.
The effect of hepatic disease on the disposition of ESTROSTEP Fe (norethindrone acetate and ethinyl estradiol tablets) has not been evaluated. However, ethinyl estradiol and norethindrone may be poorly metabolized in patients with impaired liver function.
Numerous drug-drug interactions have been reported for oral contraceptives. A summary of these is found under PRECAUTIONS: DRUG INTERACTIONS.
Last reviewed on RxList: 4/28/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Estrostep Fe Information
Estrostep Fe - User Reviews
Estrostep Fe User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.